| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.11. | BIOVIE INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.11. | BIOVIE INC. - 8-K, Current Report | - | SEC Filings | ||
| 04.11. | BioVie, Inc.: BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules | 7 | GlobeNewswire (USA) | ||
| 20.10. | BioVie reports positive bezisterim trial results in Parkinson's | 1 | Investing.com | ||
| 20.10. | BioVie meldet positive Phase-2-Ergebnisse für Bezisterim bei Parkinson | 11 | Investing.com Deutsch | ||
| 26.09. | New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global | 807 | ACCESS Newswire | Gold-backed payments, enterprise AI, a Long COVID clinical readout and AI-powered school safety lead a 6:30 p.m. ET broadcast reaching audiences across the United States, Latin America and MENA NEW... ► Artikel lesen | |
| 19.09. | New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global | 1.071 | ACCESS Newswire | BioVie (Nasdaq:BIVI) CEO Cuong Do Discusses the Company's Recent Long COVID Clinical Results and the Potential of Bezisterim to Address Significant Unmet Patient Needs NEW YORK CITY, NY / ACCESS Newswire... ► Artikel lesen | |
| BIOVIE Aktie jetzt für 0€ handeln | |||||
| 18.09. | RedChip Companies, Inc.: Alliance Entertainment and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV | 646 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / September 18, 2026 / RedChip Companies will air interviews with Alliance Entertainment Holding Corp. (Nasdaq:AENT) and BioVie Inc. (Nasdaq:BIVI) on the RedChip Small... ► Artikel lesen | |
| 16.09. | RedChip Companies, Inc.: Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results | 501 | ACCESS Newswire | BioVie CEO Cuong Do to discuss newly reported Phase 2 data showing bezisterim's potential across key Long COVID symptomsLearn why the ADDRESS-LC findings, together with recent Parkinson's data, could... ► Artikel lesen | |
| 15.09. | What's Going On With BioVie Stock on Tuesday? | 3 | Benzinga.com | ||
| 15.09. | Studienfehlschlag bei Long COVID: BioVie Aktie bricht ein | 31 | Investing.com Deutsch | ||
| 15.09. | BioVie reports phase 2 long COVID trial results | 2 | Investing.com | ||
| 15.09. | BioVie, Inc.: BioVie Announces Topline Results from Phase 2 ADDRESS-LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID | 720 | GlobeNewswire (Europe) | Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post-exertional malaise Bezisterim... ► Artikel lesen | |
| 08.09. | BioVie, Inc.: BioVie Announces Update to Parkinson's Phase 3 Development Program | 513 | GlobeNewswire (Europe) | CARSON CITY, Nev., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative... ► Artikel lesen | |
| 31.08. | BioVie, Inc.: BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID | 372 | GlobeNewswire (Europe) | CARSON CITY, Nev., Aug. 31, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative... ► Artikel lesen | |
| 14.08. | BIOVIE INC. - S-1/A, General form for registration of securities | 7 | SEC Filings | ||
| 14.08. | RedChip Companies, Inc.: First Phosphate and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV | 607 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / August 14, 2026 / RedChip Companies will air interviews with First Phosphate Corp. (NASDAQ:PHOS)(CSE:PHOS)(OTCQX:FRSPF)(FSE:KD0) and BioVie Inc. (Nasdaq:BIVI) on the... ► Artikel lesen | |
| 08.08. | New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results | 2.117 | ACCESS Newswire | Sponsored Programming Also Broadcasts Across Bloomberg Television in Latin America and MENA, Expanding the Global Reach of New to The Street's Featured Companies NEW YORK CITY, NY / ACCESS Newswire... ► Artikel lesen | |
| 07.08. | RedChip Companies, Inc.: Join Biovie's Exclusive Live Investor Webinar: Inside the SUNRISE-PD Topline Results | 1.127 | ACCESS Newswire | BioVie CEO Cuong Do to discuss the newly released Phase 2 SUNRISE-PD results and what they mean for the future development of bezisterim in Parkinson's diseaseLearn how the BioVie's differentiated approach... ► Artikel lesen | |
| 06.08. | BioVie's stock sinks 50% as company uses composite endpoint to make case for Parkinson's program | 9 | FierceBiotech |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,65 | +0,06 % | BioNTech-Aktie: Totes Kapital? | Die Aktie von BioNTech bleibt trotz des rückläufigen Impfstoffgeschäfts ein spannender Titel am Aktienmarkt. Anleger richten ihren Blick zunehmend auf die milliardenschwere Forschungspipeline im Bereich... ► Artikel lesen | |
| EVOTEC | 2,782 | -5,25 % | Evotec-Aktie: Gewinn- und Umsatzrekord? | Die Aktie des Hamburger Wirkstoffforschers Evotec bleibt ein spannender, aber risikoreicher Titel am deutschen Aktienmarkt. Nach schwierigen Monaten sorgen erste operative Fortschritte, neue Partnerschaften... ► Artikel lesen | |
| MEDIGENE | 0,003 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| AMGEN | 417,15 | -0,82 % | Amgen Announces Positive Phase 3 Results For Dazodalibep In Sjögren's Disease | Only Global Phase 3 Trial to Show Clinically Meaningful Improvements in Systemic Disease Activity and Patient-Reported Symptoms of Sjögren's Disease THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/... ► Artikel lesen | |
| NOVAVAX | 7,250 | -1,09 % | Novavax hebt Prognose an: Worauf es jetzt ankommt | ||
| STRYKER | 287,20 | +1,63 % | Stryker: 178,92-Millionen-Verkauf - was jetzt wichtig ist | ||
| BIOGEN | 228,70 | -0,13 % | Eisai, Biogen Report Five-Year Leqembi Data Showing Sustained Alzheimer's Benefit | WESTON (dpa-AFX) - Eisai Co., Ltd. (4523.T) and Biogen Inc. (BIIB) presented long-term data from the Phase 3 Clarity AD trial showing that continuous treatment with LEQEMBI (lecanemab-irmb)... ► Artikel lesen | |
| BIOFRONTERA | 2,870 | 0,00 % | Biofrontera AG: Was der Umsatzsprung nicht verrät | ||
| AAP IMPLANTATE | 1,380 | -4,83 % | aap Implantate - Aktie vor Neubewertung? CEO und COO im Interview: "Die Basis steht, jetzt schalten wir auf Wachstum." | Eine spannende Sondersituation zeichnet sich derzeit bei der aap Implantate AG (ISIN: DE000A3H2101) ab: Nach Jahren der Restrukturierung und hohen regulatorischen Aufwendungen hat der Berliner Spezialist... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,360 | +6,17 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights | VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) granted accelerated approval by U.S. Food and Drug Administration (FDA) to reduce the frequency of surgery in adults with Recurrent... ► Artikel lesen | |
| CLINUVEL | 4,479 | -5,15 % | CLINUVEL PHARMACEUTICALS LIMITED: Change in substantial holding - Updated | ||
| VIKING THERAPEUTICS | 24,900 | +2,05 % | Viking Therapeutics gains amid report of renewed takeover interest | ||
| INFLARX | 1,039 | -2,62 % | InflaRx im Check: Izicopan rückt vor, der Chart bleibt unter Druck | ||
| INTELLIA THERAPEUTICS | 9,080 | +1,34 % | Intellia auf der Jefferies Global Healthcare Conference: Marktstart und Pipeline im Fokus | ||
| TEMPUS AI | 58,00 | -1,51 % | Cathie Wood's weekly recap: boosts Nvidia, CoreWeave, Archer Aviation; pares Tempus AI, Palantir |